BOSTON--(BUSINESS WIRE)--PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Atul Pande, M.D., as the Company’s Chief Medical Officer. In this new role, Dr. Pande will oversee all clinical operations across PureTech Health’s pipeline and work closely with the team to de-risk and advance opportunities that hold the most potential for patients.
Dr. Pande commented: “I am proud and delighted to join this stellar team and hope to be instrumental in enabling the launch of some of the truly innovative medicines in the PureTech Health pipeline. Having been involved in clinical research and development for more than twenty years, I believe that the PureTech Health approach – which starts with ground-breaking science and signals of human efficacy and stresses safety – has important advantages.”
“We are excited to work more closely with Atul and to have access to his drug development expertise across PureTech Health’s pipeline,” said Daphne Zohar, Chief Executive Officer of PureTech Health. “Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms.”
Dr. Pande has more than two decades of experience in drug development. He is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. Dr. Pande has been active in the development of multiple investigational and now marketed drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer's and Parkinson's diseases. Dr. Pande is a psychiatrist and fellow of several scientific societies, including the American Psychiatric Association. He currently serves on the Board of Directors of PureTech’s Karuna Pharmaceuticals. He also sits on the Board of Axovant Sciences (NYSE:AXON), and Autifony Therapeutics and on the Scientific Advisory Board of Cennerv Pharma. Dr. Pande began his career as a faculty member at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.
About PureTech Health
PureTech
Health (PureTech Health plc, PRTC.L) is a cross-disciplinary
biopharmaceutical company creating 21st century medicines
that modulate the adaptive human systems. Our therapies target the
immune, nervous, and gastro-intestinal systems by addressing the
underlying pathophysiology of disease from a systems perspective rather
than through a single receptor or pathway. We have multiple human
proof-of-concept studies and pivotal or registration studies expected to
read out in the next two years. PureTech Health’s rich and growing
research and development pipeline has been developed in collaboration
with some of the world’s leading scientific experts who, along with
PureTech's experienced team and board, analyze more than 650 scientific
discoveries per year to identify and advance only the opportunities we
believe hold the most promise for patients. This team and process place
PureTech Health on the cutting edge of ground-breaking science and
technological innovation and leads the Company between and beyond
existing disciplines. For more information, visit www.puretechhealth.com
or connect with us on Twitter.
Forward Looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations, including,
but not limited to, those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events or
otherwise.
